{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:12:08Z","timestamp":1779343928837,"version":"3.51.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The widespread implementation of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIPs) across Latin American countries has substantially reduced pneumococcal disease burden. While the 10-valent (PCV10) and 13-valent (PCV13) vaccines have reduced morbidity and mortality, disease caused by serotypes not included in these vaccines persists. The 15-valent (PCV15) and 20-valent (PCV20) vaccines are now available in the region. This study aimed to estimate the clinical, economic, and societal burden attributable to serotypes contained in PCV10, PCV13, PCV15, and PCV20 in children aged &amp;lt;5 years in Argentina, Chile, Mexico, Colombia, and Brazil<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using country-specific epidemiological, cost, and population inputs, we applied a static Excel-based model to estimate annual pneumococcal disease cases, deaths, direct medical costs, and indirect societal costs resulting from caregiver productivity losses. Burden was estimated for serotypes included in PCV10, PCV13, PCV15, and PCV20, and results were interpreted in the context of the vaccine included in each country's pediatric NIP as of 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across the five countries, PCV20 serotypes were estimated to cause over 510,000 pneumococcal disease cases and approximately 2,700 deaths annually. This corresponded to an annual economic burden exceeding USD $182 million and a societal burden exceeding USD $34 million. Non-invasive disease, particularly pneumonia and otitis media, accounted for most of the clinical, economic, and societal burden. In countries using PCV10 in their NIP, a substantial proportion of remaining disease burden was attributable to serotypes included in PCV13 but not PCV10. Across all countries, serotypes unique to PCV15 contributed little additional burden beyond PCV13, whereas serotypes unique to PCV20 accounted for a substantial share of remaining disease burden, particularly in PCV13 NIP countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the success of PCV10 and PCV13 in reducing pneumococcal disease in Latin America, a considerable clinical, economic, and societal burden remains due to serotypes included in higher-valent vaccines. Broader serotype coverage offered by PCV20 has the potential to address this unmet burden and further reduce the public health and economic impact of pneumococcal disease in young children across the region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1768403","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:45:13Z","timestamp":1779342313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries"],"prefix":"10.3389","volume":"14","author":[{"given":"Sophie","family":"Warren","sequence":"first","affiliation":[{"name":"Global HTA, Value, & Evidence, Pfizer Inc","place":["Cambridge, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Bolanos","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Peru","place":["San Isidro, Peru"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucila","family":"Rey-Ares","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Argentina","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Reyes","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Colombia","place":["Bogota, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Huerta","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Mexico","place":["Ciudad de Mexico, CDMX, ,, Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Ranzi","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Brazil","place":["Sao Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Fernandes","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Value & Evidence, Pfizer Brazil","place":["Sao Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriela","family":"Abalos","sequence":"additional","affiliation":[{"name":"Vaccines Medical Affairs, Pfizer Argentina","place":["Buenos Aires, Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[{"name":"Global HTA, Value, & Evidence, Pfizer Inc","place":["Collegeville, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0304978","DOI":"10.1371\/journal.pone.0304978","article-title":"Invasive pneumococcal disease in Latin America and the Caribbean: serotype distribution, disease burden, and impact of vaccination. A systematic review and meta-analysis","volume":"19","author":"Bardach","year":"2024","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14760584.2017.1334555","article-title":"Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?","volume":"16","author":"Avila-Aguero","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B3","unstructured":"Rapid vaccine supply diagnostic for Latin America and Caribbean region: Scaling up of Immunization Capacities in the PROSUR countries\n          \n          \n            \n              Malvoti\n              S\n            \n            \n              Soble\n              A\n            \n          \n          \n          2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jpids\/piw089","article-title":"Rapid decrease in rates of hospitalization resulting from invasive pneumococcal disease and community-acquired pneumonia in children aged <60 months after 13-valent pneumococcal conjugate vaccine introduction in Argentina","volume":"7","author":"L\u00f3pez","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1093\/ofid\/ofx163.1820","article-title":"Continuous pneumococcal invasive disease reduction, high impact on pneumococcal empyemas and meningitis, and serotype 19A disappearance following PCV-13 vaccination in children: eleven and a half years of active surveillance in a Mexican hospital on the U.S. Border","volume":"4","author":"Chacon-Cruz","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0153141","DOI":"10.1371\/journal.pone.0153141","article-title":"Effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV-10) in children in Chile: a nested case-control study using nationwide pneumonia morbidity and mortality surveillance data","volume":"11","author":"Diaz","year":"2016","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s40121-021-00544-1","article-title":"Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age","volume":"10","author":"Wasserman","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40121-023-00780-7","article-title":"Reanalysis of the clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children <5 age: a societal perspective","volume":"12","author":"Li","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40121-022-00699-5","article-title":"PCV13 Pediatric routine schedule completion and adherence before and during the COVID-19 pandemic in the United States","volume":"11","author":"Huang","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/vaccines12101197","article-title":"Burden of pneumococcal disease in young children due to serotypes contained in different pneumococcal conjugate vaccines in eight Asian countries and territories","volume":"12","author":"Huang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B11","doi-asserted-by":"publisher","year":"2025","DOI":"10.37774\/9789275330166"},{"key":"B12","doi-asserted-by":"publisher","year":"2021","DOI":"10.37774\/9789275324035"},{"key":"B13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.vaccine.2021.12.008","article-title":"Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006\u20132019. Temporal progression of serotypes distribution and antibiotic resistance","volume":"40","author":"Zintgraff","year":"2022","journal-title":"Vaccine"},{"key":"B14","article-title":"Datos por sexo y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Streptococcus pneumoniae y Neisseria meningitidis en procesos infecciosos","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14760584.2021.1971521","article-title":"Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges","volume":"20","author":"Horn","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/vaccines11081369","article-title":"Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants","volume":"11","author":"Warren","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2400751","DOI":"10.1080\/21645515.2024.2400751","article-title":"An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population","volume":"20","author":"Fridh","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40121-024-00977-4","article-title":"Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: a German societal perspective analysis","volume":"13","author":"Ta","year":"2024","journal-title":"Infect Dis Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2257426","DOI":"10.1080\/21645515.2023.2257426","article-title":"Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population","volume":"19","author":"Lytle","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0150949","DOI":"10.1371\/journal.pone.0150949","article-title":"Predominant Bacteria detected from the middle ear fluid of children experiencing Otitis Media: a systematic review","volume":"11","author":"Ngo","year":"2016","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"126043","DOI":"10.1016\/j.vaccine.2024.06.011","article-title":"Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina","volume":"42","author":"Rey-Ares","year":"2024","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1080\/21645515.2021.1972709","article-title":"Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact","volume":"17","author":"Guevara","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B23","first-page":"502","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of consolidated pneumonia in children younger than 5 years old in Pilar, Buenos Aires: a population-based study","volume":"113","author":"Gentile","year":"2015","journal-title":"Arch Argent Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1478-7547-11-21","article-title":"A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries","volume":"11","author":"Mart\u00ed","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","article-title":"Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina","volume":"29","author":"Urue\u00f1a","year":"2011","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2475594","DOI":"10.1080\/21645515.2025.2475594","article-title":"PCV20 For the prevention of invasive pneumococcal disease in the Mexican pediatric population: a cost-effectiveness analysis","volume":"21","author":"Huerta","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/21645515.2018.1516491","article-title":"Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico","volume":"15","author":"Wasserman","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B28","unstructured":"Anuario de Morbilidad 2019: Neumon\u00edas y bronconeumon\u00edas, por grupo de edad. M\u00e9xico: SSA\/DGE\n          \n          \n          2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.26633\/RPSP.2018.155","article-title":"Impact of the 10-valent pneumococcal conjugate vaccine on the southern area of Santiago (Chile), 2009\u20132015","volume":"42","author":"Alvarado","year":"2018","journal-title":"Revista Panamericana de Salud Publica"},{"key":"B30","volume-title":"Registro Individual de Prestaciones en Salud - RIPS-SISPRO","year":"2026"},{"key":"B31","year":"2026"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S665","DOI":"10.1093\/ofid\/ofab466.1340","article-title":"1147. Sentinel surveillance of bacterial pneumonia in children under 5 years treated in HOMI - fundaci\u00f3n hospital pediatrico la misericordia in bogot\u00e1, Colombia 2016\u20132020","volume":"8","author":"Moreno","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1380125","DOI":"10.3389\/fmed.2024.1380125","article-title":"Serotype distribution, clinical characteristics, and antimicrobial resistance of pediatric invasive pneumococcal disease in Colombia during PCV10 mass vaccination (2017\u20132022)","volume":"11","author":"Camacho-Moreno","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/21645515.2020.1809266","article-title":"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants","volume":"17","author":"Perdrizet","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0184204","DOI":"10.1371\/journal.pone.0184204","article-title":"Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: a time-series analysis","volume":"12","author":"Andrade","year":"2017","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0179222","DOI":"10.1371\/journal.pone.0179222","article-title":"Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil","volume":"12","author":"Sartori","year":"2017","journal-title":"PLoS One"},{"key":"B37","volume-title":"Poblaci\u00f3n por Sexo y Grupos Quinquenales de Edad. A\u00f1os 2010\u20132040","year":"2023"},{"key":"B38","volume-title":"Poblaci\u00f3n Total por Entidad Federativa y Grupo Quinquenal de Edad Seg\u00fan Sexo, Serie de A\u00f1os Censales de 1990 a 2020","year":"2020"},{"key":"B39","volume-title":"Poblaci\u00f3n Total por Sexo y \u00e1rea urbana-rural, Seg\u00fan Regi\u00f3n y Grupos de Edad","year":"2017"},{"key":"B40","volume-title":"Colombia. National and Departmental Estimates 1985-2005 and Projections 2005-2020 Disaggregated by sex, Area and Five-year age Groups","year":"2020"},{"key":"B41","article-title":"Tabela 9514: Popula\u00e7\u00e3o Residente, por Sexo, Idade e Forma de Declara\u00e7\u00e3o da Idade","year":"2022"},{"key":"B42","volume-title":"SIREVA 2019: Argentina","year":"2019"},{"key":"B43","year":""},{"key":"B44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/14760584.2023.2184090","article-title":"A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia","volume":"22","author":"Ord\u00f3\u00f1ez","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1542\/peds.2008-1702","article-title":"Serotype 19A is the most common serotype causing invasive pneumococcal infections in children","volume":"125","author":"Kaplan","year":"2010","journal-title":"Pediatrics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.vaccine.2010.10.032","article-title":"Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease","volume":"29","author":"Yildirim","year":"2010","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10096-011-1468-7","article-title":"Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR","volume":"31","author":"Selva","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.vaccine.2019.07.043","article-title":"Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil","volume":"37","author":"Brandileone","year":"2019","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/j.vaccine.2022.03.022","article-title":"Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in bogota, Colombia, 2008\u20132019","volume":"40","author":"Guti\u00e9rrez-Tobar","year":"2022","journal-title":"Vaccine"},{"key":"B51","volume-title":"Reuni\u00f3n de la Comisi\u00f3n Nacional de Inmunizaci\u00f3n","year":"2024"},{"key":"B52","year":"2023"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.jvacx.2023.100364","article-title":"Comparative estimates of crude coverage of the Mexican immunization program: findings from a national survey","volume":"15","author":"Ang\u00e9lica","year":"2023","journal-title":"Vaccine X"},{"key":"B54","year":"2024"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B56","volume-title":"Ordinance No. 6, January 8, 2026. Incorporate into the Unified Health System (SUS), the Pneumococcal Conjugate Vaccines for Immunization of Children up to 5 Years of age Against Pneumococcal Disease, According to a Strategy to be Defined by the National Immunization Program (NIP)","year":"2026"},{"key":"B57","article-title":"Lineamientos t\u00e9cnicos y operativos para la transici\u00f3n de la vacuna polisac\u00e1rida contra el neumococo de PCV10 a PCV13 en Colombia 2022","year":"2022"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: spIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1768403\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:45:19Z","timestamp":1779342319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1768403\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":58,"alternative-id":["10.3389\/fped.2026.1768403"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1768403","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1768403"}}